Physician profile
Stuart Shafer
NPI 1003818816
$108,040.22
in general payments reported to CMS, 2019-2025
78 companies · $3,114 in 2025
The $3,114 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $18K · 2021: $16K · 2022: $10K · 2023: $2,346 · 2024: $1,946 · 2025: $3,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,211 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,211.12 |
| Education | $194.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $39,157.02 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Genzyme Corporation | $30,442.74 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $10,912.49 | 2020-2024 | Acthar |
| Mallinckrodt Enterprises LLC | $6,913.91 | 2019 | |
| Biogen, INC. | $6,405.30 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $3,915.46 | 2019-2025 | |
| Emd Serono, INC. | $1,881.92 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $697.93 | 2020-2025 | Qulipta, Ubrelvy, Botox |
| Pfizer INC. | $607.74 | 2019-2025 | |
| Lilly USA, LLC | $567.90 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $465.54 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alexion Pharmaceuticals, INC. | $362.26 | 2019-2025 | Ultomiris, Soliris |
| Sunovion Pharmaceuticals INC. | $325.91 | 2019-2022 | |
| Eisai INC. | $314.00 | 2023-2025 | |
| Ucb, INC. | $312.10 | 2020-2025 | Zilbrysq, Briviact, Rystiggo |
Show all 68 companies
10 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$80,684.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Shafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.